468
Participants
Start Date
August 31, 2002
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
Interferon beta-1b (Betaseron, BAY86-5046)
Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
Interferon beta-1b (Betaseron, BAY86-5046)
Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
Budapest
Vienna
Budapest
Brussels
Budapest
Ljubljana
Glostrup Municipality
Leuven
Coimbra
Liège
Basel
Debrecen
Innsbruck
Szeged
Graz
Ghent
Sankt Gallen
Prague
Torino
Berlin
Prague
Berlin
Hennigsdorf
Greifswald
Lublin
Turku
Milan
Gallarate
Dijon
Pavia
Madrid
Málaga
Pilsen
Toulouse
Krakow
Bordeaux
Tampere
Haifa
Rennes
Marburg
Padua
Giessen
Göttingen
Braunschweig
Magdeburg
Düsseldorf
Düsseldorf
Seville
Gothenburg
Valencia
Münster
Barakaldo
Hradec Králové
Wroclaw
Cologne
Tel Litwinsky
Nancy
Mainz
Lille
Seinäjoki
Clermont-Ferrand
Offenbach
Brno
Homburg
Kuopio
Ostrava
Paris
München
Bydgoszcz
Ulm
Oulu
Lodz
Regensburg
Würzburg
Erfurt
Calgary
Vancouver
London
Ottawa
Toronto
Montreal
Helsinki
Nice
Halle
Sittard
Tilburg
Bergen
L'Hospitalet de Llobregat
Barcelona
Barcelona
Dundee
Aberdeen
London
Sheffield
Lead Sponsor
Bayer
INDUSTRY